LY3435151 / Eli Lilly - LARVOL DELTA

A Study of LY3435151 in Participants With Solid Tumors (clinicaltrials.gov) - P1a/1b; N=2; Terminated; Sponsor: Eli Lilly and Company; N=230 ➔ 2; Recruiting ➔ Terminated; Study terminated due to strategic business decision by Eli Lilly and Company.

Clinical • Enrollment change • Trial termination • Breast Cancer • Cervical Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Hepatocellular Cancer • Leiomyosarcoma • Liver Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Uterine Leiomyoma • Women's Health

A Study of LY3435151 in Participants With Solid Tumors (clinicaltrials.gov) - P1a/1b; N=230; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Jan 2023 ➔ Jun 2020; Trial primary completion date: Jan 2023 ➔ Jun 2020

Clinical • Trial completion date • Trial primary completion date

A Study of LY3435151 in Participants With Solid Tumors (clinicaltrials.gov) - P1a/1b; N=230; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open